Full history for every metric is available with a Kvantra account
Key financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CHF m | 731 | 947 | 1,144 | 1,074 | 934 | 882 | 871 | 885 |
| Operating profit | CHF m | 25 | 40 | ||||||
| Net profit | CHF m | 104 | 122 | 121 | 132 | 68 | -111 | -116 | 82 |
| EPS reported | CHF | -8.74 | -9.16 | ||||||
| Operating cashflow per share | CHF | 10.90 | 7.67 | ||||||
| Capex per share | CHF | 2.79 | 2.91 | ||||||
| FCF per share | CHF | 8.11 | 4.76 | ||||||
| Free cash flow | CHF m | 103 | 59 | ||||||
| Net debt | CHF m | -161 | -73 | ||||||
| Book value equity | CHF m | 1,151 | 1,118 | ||||||
| Book value per share | CHF | 90.95 | 90.17 | ||||||
| Number of shares | m | 12.66 | 12.4 | ||||||
| DPS (TTM paid) | CHF | 3.00 | 3.00 |
Financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.41 | 2.62 | ||||||
| P/S LTM | x | 1.84 | 3.36 | ||||||
| P/FCF LTM | x | 15.85 | 49.57 | ||||||
| EV/EBITDA LTM | x | 19.35 | 29.09 | ||||||
| EV/Sales LTM | x | 1.89 | 3.28 | ||||||
| Earnings Yield LTM | % | -6.80% | -4.06% | ||||||
| FCF Yield | % | 6.31% | 2.02% | ||||||
| Quality | |||||||||
| ROE | % | -9.61% | -10.25% | ||||||
| ROIC | % | 1.78% | 2.91% | ||||||
| Operating margin | % | 2.86% | 4.60% | ||||||
| Gross margin | % | 31.75% | 34.06% | ||||||
| FCF/Sales | % | 11.63% | 6.78% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -5.54% | -3.98% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | -12.89% | -60.68% | ||||||
| Operating Profit Growth | % | -66.60% | -41.93% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 2.34% | 1.30% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | -34.37% | -34.37% | ||||||
| FCF/Debt | x | 0.47 | 0.28 | ||||||
| Net Debt/EBITDA | x | 0.49 | 0.92 | ||||||
| EBIT/Net interest | x | 7.60 | 13.02 | ||||||
| Net debt/market cap | % | -9.90% | -2.50% | ||||||
| Net debt/Equity | x | -0.14 | -0.07 | ||||||
| Gross debt/equity | x | 0.19 | 0.19 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Tecan Group AG, established in 1980 and headquartered in Männedorf, Switzerland, specializes in providing cutting-edge laboratory instruments and holistic solutions. The company caters to a broad spectrum of clients, including pharmaceutical and biotechnology corporations, university research departments, and forensic and diagnostic laboratories. Its operations are structured into two principal segments: Life Sciences Business and Partnering Business. Tecan's extensive product portfolio features automated liquid handling systems, microplate readers and washers, various consumables, reagents for Next-Generation Sequencing (NGS), immunoassays, microbodies, and specialized software. Key proprietary solutions include Tecan Laberwax for automated workflows and Resolvex, an intelligent sample preparation system applicable across diverse fields such as genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA. Additionally, Tecan develops and manufactures crucial components—like precision pumps, valves, robotic arms, and developer software—for other laboratory instrument producers serving life science research, diagnostics, and various industrial applications. Its advanced platform-based automation solutions include Synergence, Freedom EVO, and Fluent instruments. The company's global footprint spans Switzerland, other European nations, North America, Asia, and other international markets.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
Tecan Group AG, established in 1980 and headquartered in Männedorf, Switzerland, specializes in providing cutting-edge laboratory instruments and holistic solutions. The company caters to a broad spectrum of clients, including pharmaceutical and biotechnology corporations, university research departments, and forensic and diagnostic laboratories. Its operations are structured into two principal segments: Life Sciences Business and Partnering Business. Tecan's extensive product portfolio features automated liquid handling systems, microplate readers and washers, various consumables, reagents for Next-Generation Sequencing (NGS), immunoassays, microbodies, and specialized software. Key proprietary solutions include Tecan Laberwax for automated workflows and Resolvex, an intelligent sample preparation system applicable across diverse fields such as genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA. Additionally, Tecan develops and manufactures crucial components—like precision pumps, valves, robotic arms, and developer software—for other laboratory instrument producers serving life science research, diagnostics, and various industrial applications. Its advanced platform-based automation solutions include Synergence, Freedom EVO, and Fluent instruments. The company's global footprint spans Switzerland, other European nations, North America, Asia, and other international markets.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free